Worldwide Influenza Vaccines Market Size, Share, Analysis, Growth, Trends, and Forecast to 2027

March 2020 | 260 pages | ID: WD98ABABEB8BEN
DPI Research

Abstracts

Worldwide Influenza Vaccines Market size is expected to exceed USD 7.5 billion by 2027.

Highlighted with 23 tables and 100 figures, this 260-page report “Worldwide Influenza Vaccines Market Size, Share, Analysis, Growth, Trends, and Forecast to 2027” is based on a comprehensive research of the worldwide influenza vaccines market. The report offers the most up-to-date industry data on the actual market situation and future outlook for the worldwide influenza vaccines market. The report provides historical market data for 2013 – 2019, and forecasts from 2020 until 2027. A comprehensive analysis has been done on market share with the percentage of all the segments.

The report contains a deep analysis of the worldwide influenza vaccines market with size in terms of both value and volume. The report provides a clear insight into current and future developments of the worldwide influenza vaccines market. The report also explores a detailed analysis of the children and adults vaccinated with influenza vaccines worldwide from 2013 to 2019 and forecasts to 2027. It provides essential insights into influenza vaccines market revenue for the top 21 regional and national, and forecast until 2027.

Key trends in terms of collaboration deals, merger & acquisitions, distribution, exclusive and licensing agreement are analyzed with details. The report also offers detailed information about the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase. The report also investigates detailed insights about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU, and Japan. The report also delivers a detailed assessment of the latest happenings in the influenza vaccines market worldwide. The report also examines the main market growth driving and restraining forces and also gives an all-round future outlook through 2027.

The report concludes with the profiles of the key players in the worldwide influenza vaccines market. The key players are evaluated on various parameters such as business overview, vaccines portfolio, promising vaccines in the clinical development, influenza vaccines sales value analysis, and recent development.

Other emerging players are making novel technology-based vaccines that are likely to affect the market share during the forecast period. The emerging players are evaluated on various parameters such as business overview, promising vaccines in the clinical development with phase, platform technology, and recent development.

The Report Analyses the Market Based on Countries and Presents the Forecast in Terms of Value and Volume for the Next Seven Years. Countries Covered in the Report Include:

1) United States
2) Canada
3) Brazil
4) Germany
5) France
6) Italy
7) Spain
8) United Kingdom
9) Netherlands
10) Sweden
11) Denmark
12) Poland
13) Norway
14) Finland
15) Ireland
16) Belgium
17) Australia
18) New Zealand
19) Japan
20) China
21) India

The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:

• Sanofi Pasteur
• GlaxoSmithKline (GSK)
• Seqirus (CSL Limited)
• AstraZeneca
• Mylan
• Gamma Vaccines Pty Ltd.
• Hualan Biological Engineering Inc.
• Shanghai Institute of Biological Products Co., Ltd.
• BioDiem
• Novavax
• BiondVax Pharmaceuticals Ltd.
• Medicago
• Moderna Inc
• Pneumagen
• Daiichi–Sankyo
• Altimmune
• FluGen
• Imutex

Report Scope

• The Market Size of the Worldwide Influenza Vaccines Market with Seven Years Forecast
• The Market Size of the Regional and National Influenza Vaccines Market with Seven Years Forecast
• Scrutinizes the Worldwide Overall Persons Being Vaccinated with Influenza Vaccines
• Scrutinizes the Regional and National Persons Being Vaccinated with Influenza Vaccines
• Delivers a Latest Happenings in the Worldwide Influenza Vaccines Market
• Detailed Insights of the Regulatory Framework Including the Approval Process and an Overview of the Regulatory Authorities in the United States, EU, and Japan
• Provides Key Trends with Respect to Collaboration Deals, Merger & Acquisitions, Distribution, Exclusive and Licensing Agreement
• Reviews Most Recent Clinical Trials of the Influenza Vaccines
• A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolios, Promising Vaccines in the Clinical Development, Sales Value Analysis, and Recent Development
• An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development

The Report Helps Answer the Following Questions:

• What is the current size of the worldwide influenza vaccines market? How much will this market be worth from 2020 to 2027?
• How many persons being vaccinated with influenza vaccines worldwide during 2013 – 2027?
• Which country is expected to hold the highest market share in the worldwide influenza vaccine market?
• What are the main drivers and restraints in the worldwide influenza vaccines market?
• What are the major deals happenings in the worldwide influenza vaccines market?
• Who are the top players and what are their activities, revenue, recent developments, and prospects?
• What are some of the most prominent influenza vaccines currently in development? What are their activities, phase, platform technology, and recent developments?

Contents

1. EXECUTIVE SUMMARY

2. WORLDWIDE NUMBER OF PERSONS VACCINATED WITH INFLUENZA VACCINES AND FORECAST (2013 – 2027)

3. WORLDWIDE INFLUENZA VACCINES MARKET REVENUE AND FORECAST (2013 – 2027)

4. WORLDWIDE INFLUENZA VACCINES MARKET SHARE AND Y–O–Y GROWTH (%)

4.1 Number of Persons Vaccinated with Influenza Vaccines Share,2013 – 2027(%)
4.2 Influenza Vaccines Market Share,2013 - 2027(%)

5. WORLDWIDE INFLUENZA VACCINES MARKET DRIVERS AND INHIBITORS

5.1 Market Drivers
5.2 Market Inhibitors

6. WORLDWIDE INFLUENZA VACCINES MARKET, BY GEOGRAPHY (VOLUME AND VALUE),2013 – 2027

6.1 United States
  6.1.1 United States Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.1.2 United States Influenza Vaccines Market Revenue (2013 – 2027)
6.2 Canada
  6.2.1 Canada Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.2.2 Canada Influenza Vaccines Market Revenue (2013 – 2027)
6.3 Germany
  6.3.1 Germany Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.3.2 Germany Influenza Vaccines Market Revenue (2013 – 2027)
6.4 France
  6.4.1 France Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.4.2 France Influenza Vaccines Market Revenue (2013 – 2027)
6.5 Italy
  6.5.1 Italy Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.5.2 Italy Influenza Vaccines Market Revenue (2013 – 2027)
6.6 Spain
  6.6.1 Spain Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.6.2 Spain Influenza Vaccines Market Revenue (2013 – 2027)
6.7 United Kingdom
  6.7.1 United Kingdom Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.7.2 United Kingdom Influenza Vaccines Market Revenue (2013 – 2027)
6.8 Netherlands
  6.8.1 Netherlands Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.8.2 Netherlands Influenza Vaccines Market Revenue (2013 – 2027)
6.9 Sweden
  6.9.1 Sweden Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.9.2 Sweden Influenza Vaccines Market Revenue (2013 – 2027)
6.10 Denmark
  6.10.1 Denmark Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.10.2 Denmark Influenza Vaccines Market Revenue (2013 – 2027)
6.11 Poland
  6.11.1 Poland Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.11.2 Poland Influenza Vaccines Market Revenue (2013 – 2027)
6.12 Norway
  6.12.1 Norway Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.12.2 Norway Influenza Vaccines Market Revenue (2013 – 2027)
6.13 Finland
  6.13.1 Finland Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.13.2 Finland Influenza Vaccines Market Revenue (2013 – 2027)
6.14 Ireland
  6.14.1 Ireland Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.14.2 Ireland Influenza Vaccines Market Revenue (2013 – 2027)
6.15 Belgium
  6.15.1 Belgium Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.15.2 Belgium Influenza Vaccines Market Revenue (2013 – 2027)
6.16 Australia
  6.16.1 Australia Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.16.2 Australia Influenza Vaccines Market Revenue (2013 – 2027)
6.17 New Zealand
  6.17.1 New Zealand Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.17.2 New Zealand Influenza Vaccines Market Revenue (2013 – 2027)
6.18 Japan
  6.18.1 Japan Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.18.2 Japan Influenza Vaccines Market Revenue (2013 – 2027)
6.19 Brazil
  6.19.1 Brazil Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.19.2 Brazil Influenza Vaccines Market Revenue (2013 – 2027)
6.20 China
  6.20.1 China Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.20.2 China Influenza Vaccines Market Revenue (2013 – 2027)
6.21 India
  6.21.1 India Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.21.2 India Influenza Vaccines Market Revenue (2013 – 2027)
6.22 Rest of the World (ROW)
  6.22.1 ROW Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
  6.22.2 ROW Influenza Vaccines Market Revenue (2013 – 2027)

7. RECENT DEVELOPMENT IN THE WORLDWIDE INFLUENZA VACCINES MARKET

8. WORLDWIDE INFLUENZA VACCINES MARKET – REGULATORY SYSTEM

8.1 United States
8.2 Europe
8.3 Japan

9. MAJOR DEALS IN THE WORLDWIDE INFLUENZA VACCINES MARKET

9.1 Merger and Acquisitions
9.2 Collaboration Deals
9.3 Licensing Agreement
9.4 Exclusive Agreement
9.5 Distribution Agreement

10. INFLUENZA VACCINES CLINICAL TRIAL INSIGHTS BY PHASE, COMPANY & COUNTRY

10.1 Year 2020
10.2 Year 2019

11. KEY COMPANIES ANALYSIS

11.1 Sanofi Pasteur
  11.1.1 Business Overview
  11.1.2 Influenza Vaccines Portfolio
  11.1.3 Influenza Vaccines Value Sales Analysis
  11.1.4 Promising Influenza Vaccines in the Clinical Development
  11.1.5 Recent Development
11.2 GlaxoSmithKline (GSK)
  11.2.1 Business Overview
  11.2.2 Influenza Vaccines Portfolio
  11.2.3 Influenza Vaccines Sales Value Analysis
  11.2.4 Recent Development
11.3 Seqirus (CSL Limited)
  11.3.1 Business Overview
  11.3.2 Influenza Vaccines Portfolios
  11.3.3 Influenza Vaccines Sales Value Analysis
  11.3.4 Promising Influenza Vaccines in the Clinical Development
  11.3.5 Recent Development
11.4 AstraZeneca
  11.4.1 Business Overview
  11.4.2 Influenza Vaccines Portfolio
  11.4.3 Influenza Vaccines Sales Value Analysis
  11.4.4 Recent Development
11.5 Gamma Vaccines Pty Ltd
  11.5.1 Business Overview
  11.5.2 Influenza Vaccines Portfolio
  11.5.3 Recent Development
11.6 Hualan Biological Engineering Inc
  11.6.1 Business Overview
  11.6.2 Influenza Vaccines Portfolio
  11.6.3 Recent Development
11.7 Shanghai Institute of Biological Products Co., Ltd.
  11.7.1 Business Overview
  11.7.2 Influenza Vaccine Portfolio
11.8 Mylan
  11.8.1 Business Overview
  11.8.2 Influenza Vaccine Portfolio
11.9 BioDiem
  11.9.1 Business Overview
  11.9.2 Influenza Vaccine Portfolio
  11.9.3 Recent Development

12. EMERGING PLAYERS

12.1 Novavax
  12.1.1 Business Overview
  12.1.2 Promising Influenza Vaccines in the Clinical Development
  12.1.3 Recent Development
12.2 BiondVax Pharmaceuticals Ltd.
  12.2.1 Business Overview
  12.2.2 Promising Influenza Vaccines in the Clinical Development
  12.2.3 Recent Development
12.3 Medicago
  12.3.1 Business Overview
  12.3.2 Promising Influenza Vaccines in the Clinical Development
  12.3.3 Recent Development
12.4 Moderna Inc
  12.4.1 Business Overview
  12.4.2 Promising Influenza Vaccines in the Clinical Development
  12.4.3 Recent Development
12.5 Pneumagen
  12.5.1 Business Overview
  12.5.2 Promising Influenza Vaccines in the Clinical Development
  12.5.3 Recent Development
12.6 Altimmune
  12.6.1 Business Overview
  12.6.2 Promising Influenza Vaccines in the Clinical Development
  12.6.3 Recent Development
12.7 Daiichi Sankyo
  12.7.1 Business Overview
  12.7.2 Promising Influenza Vaccines in the Clinical Development
  12.7.3 Recent Development
12.8 FluGen
  12.8.1 Business Overview
  12.8.2 Promising Influenza Vaccines in the Clinical Development
  12.8.3 Recent Development
12.9 Imutex
  12.9.1 Business Overview
  12.9.2 Promising Vaccines in the Clinical Development

List Of Tables

LIST OF TABLES

Table 4–1: Worldwide Number of Persons Vaccinated with Influenza Vaccines Share (Percent),2013 – 2019
Table 4–2: Worldwide Number of Persons Vaccinated with Influenza Vaccines Share Forecast (Percent),2020 – 2027
Table 4–3: Worldwide Influenza Vaccines Market Share (Percent),2013 – 2019
Table 4–4: Worldwide Influenza Vaccines Market Share Forecast (Percent),2020 – 2027
Table 8–1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 8–2: European Union – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 8–3: Japan – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 9–1: Merger & Acquisitions in the Influenza Vaccines Market
Table 9–2: Collaboration Deal in the Influenza Vaccines Market
Table 9–3: Licensing Agreement in the Influenza Vaccines Market
Table 9–4: Exclusive Agreement in the Influenza Vaccines Market
Table 9–5: Distribution Agreement in the Influenza Vaccines Market
Table 11–1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 11–2: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 12–1: Novavax Promising Influenza Vaccines in the Clinical Development
Table 12–2: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 12–3: Medicago Promising Influenza Vaccines in the Clinical Development
Table 12–4: Moderna Promising Influenza Vaccines in the Clinical Development
Table 12–5: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 12–6: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 12–7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 12–8: FluGen Promising Influenza Vaccines in the Clinical Development
Table 12–9: Imutex Promising Influenza Vaccines in the Clinical Development

List Of Figures

LIST OF FIGURES

Figure 2–1: Worldwide Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 2–2: Worldwide Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand),2020 – 2027
Figure 3–1: Worldwide Influenza Vaccines Market (Million US$),2013 – 2019
Figure 3–2: Worldwide Influenza Vaccines Market Forecast (Million US$),2020 – 2027
Figure 6–1: United States Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019
Figure 6–2: United States Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–3: United States Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–4: United States Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–5: Canada Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019
Figure 6–6: Canada Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–7: Canada Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–8: Canada Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–9: Germany Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019
Figure 6–10: Germany Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–11: Germany Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–12: Germany Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–13: France Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019
Figure 6–14: France Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–15: France Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–16: France Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–17: Italy Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019
Figure 6–18: Italy Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–19: Italy Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–20: Italy Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–21: Spain Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019
Figure 6–22: Spain Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–23: Spain Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–24: Spain Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–25: United Kingdom Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019
Figure 6–26: United Kingdom Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand),2020 – 2027
Figure 6–27: United Kingdom Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–28: United Kingdom Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–29: Netherlands Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–30: Netherlands Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–31: Netherlands Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–32: Netherlands Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–33: Sweden Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–34: Sweden Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–35: Sweden Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–36: Sweden Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–37: Denmark Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–38: Denmark Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–39: Denmark Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–40: Denmark Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–41: Poland Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–42: Poland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–43: Poland Influenza Vaccines Revenue Market (Million US$),2013 – 2019
Figure 6–44: Poland Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–45: Norway Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–46: Norway Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–47: Norway Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–48: Norway Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–49: Finland Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–50: Finland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–51: Finland Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–52: Finland Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–53: Ireland Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–54: Ireland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–55: Ireland Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–56: Ireland Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–57: Belgium Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–58: Belgium Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2027
Figure 6–59: Belgium Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–60: Belgium Influenza Vaccines Market Revenue Forecast (Million US$),2019 – 2027
Figure 6–61: Australia Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–62: Australia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–63: Australia Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–64: Australia Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–65: New Zealand Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–66: New Zealand Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–67: New Zealand Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–68: New Zealand Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–69: Japan Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–70: Japan Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2027
Figure 6–71: Japan Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–72: Japan Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–73: Brazil Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–74: Brazil Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2027
Figure 6–75: Brazil Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–76: Brazil Influenza Vaccines Market Revenue Forecast (Million US$),2019 – 2027
Figure 6–77: China Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–78: China Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2027
Figure 6–79: China Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–80: China Influenza Vaccines Market Revenue Forecast (Million US$),2019 – 2027
Figure 6–81: India Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–82: India Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2027
Figure 6–83: India Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–84: India Influenza Vaccines Market Revenue Forecast (Million US$),2019 – 2027
Figure 6–85: ROW Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–86: ROW Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–87: ROW Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–88: ROW Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 12–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2013 – 2019
Figure 12–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027
Figure 12–3: GSK Influenza Vaccines Net Sales Value (Million US$),2013 – 2019
Figure 12–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027
Figure 12–3: Seqirus Influenza Vaccines Net Sales Value (Million US$),2013 – 2019
Figure 12–4: Sequirus Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027
Figure 12–5: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2013 – 2019
Figure 12–6: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2019 – 2027